Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285491862> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4285491862 endingPage "635" @default.
- W4285491862 startingPage "627" @default.
- W4285491862 abstract "BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS by blocking the signal transduction of interleukin-6 (IL-6). OBJECTIVE: To evaluate the clinical and laboratory parameters associated with mortality among patients receiving tocilizumab treatment. DESIGN AND SETTING: Retrospective observational study conducted in the chest disease departments of two different training and research hospitals in the center of Ankara, Turkey. METHODS: Patients who were hospitalized and treated with tocilizumab in September 2020 were retrospectively analyzed. Their laboratory parameters and clinical characteristics were obtained from the hospital information system database. Comparative analyses were performed between the patients who died and the ones who survived. RESULTS: A total of 58 patients who received tocilizumab treatment were included in this study, among whom 35 (60.3%) died. There was no difference between the mortality and survival groups in terms of white blood cell (WBC), neutrophil, lymphocyte, ferritin or C-reactive protein (CRP) levels detected on admission. WBC, lymphocyte, neutrophil and CRP levels measured on the third and fifth days after tocilizumab administration were found to be significantly lower in the survival group (P < 0.05). In multiple logistic regression analysis, age and oxygen saturation were determined to be independent risk factors for mortality. CONCLUSION: Persistently high WBC, CRP and neutrophil levels and low lymphocyte levels could be considered to be valuable indicators of mortality among COVID-19 patients treated with tocilizumab. Age and low oxygen saturation are independent risk factors for mortality among patients receiving tocilizumab treatment." @default.
- W4285491862 created "2022-07-15" @default.
- W4285491862 creator A5003414078 @default.
- W4285491862 creator A5021460458 @default.
- W4285491862 creator A5051465397 @default.
- W4285491862 date "2022-10-01" @default.
- W4285491862 modified "2023-10-16" @default.
- W4285491862 title "Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study" @default.
- W4285491862 cites W2097147259 @default.
- W4285491862 cites W2104917657 @default.
- W4285491862 cites W2105400883 @default.
- W4285491862 cites W2110995918 @default.
- W4285491862 cites W2617620062 @default.
- W4285491862 cites W2788008397 @default.
- W4285491862 cites W2804159084 @default.
- W4285491862 cites W2808166290 @default.
- W4285491862 cites W3002108456 @default.
- W4285491862 cites W3003749070 @default.
- W4285491862 cites W3007940623 @default.
- W4285491862 cites W3008028633 @default.
- W4285491862 cites W3009314935 @default.
- W4285491862 cites W3014333693 @default.
- W4285491862 cites W3022381041 @default.
- W4285491862 cites W3022970339 @default.
- W4285491862 cites W3024848265 @default.
- W4285491862 cites W3031136549 @default.
- W4285491862 cites W3042021285 @default.
- W4285491862 cites W3092623037 @default.
- W4285491862 cites W3094209984 @default.
- W4285491862 cites W3127007629 @default.
- W4285491862 cites W3128647292 @default.
- W4285491862 cites W3129869280 @default.
- W4285491862 cites W3165656738 @default.
- W4285491862 doi "https://doi.org/10.1590/1516-3180.2021.0604.r1.23112021" @default.
- W4285491862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35858016" @default.
- W4285491862 hasPublicationYear "2022" @default.
- W4285491862 type Work @default.
- W4285491862 citedByCount "1" @default.
- W4285491862 countsByYear W42854918622022 @default.
- W4285491862 crossrefType "journal-article" @default.
- W4285491862 hasAuthorship W4285491862A5003414078 @default.
- W4285491862 hasAuthorship W4285491862A5021460458 @default.
- W4285491862 hasAuthorship W4285491862A5051465397 @default.
- W4285491862 hasBestOaLocation W42854918621 @default.
- W4285491862 hasConcept C126322002 @default.
- W4285491862 hasConcept C167135981 @default.
- W4285491862 hasConcept C23131810 @default.
- W4285491862 hasConcept C2777178219 @default.
- W4285491862 hasConcept C2778488018 @default.
- W4285491862 hasConcept C2779134260 @default.
- W4285491862 hasConcept C71924100 @default.
- W4285491862 hasConceptScore W4285491862C126322002 @default.
- W4285491862 hasConceptScore W4285491862C167135981 @default.
- W4285491862 hasConceptScore W4285491862C23131810 @default.
- W4285491862 hasConceptScore W4285491862C2777178219 @default.
- W4285491862 hasConceptScore W4285491862C2778488018 @default.
- W4285491862 hasConceptScore W4285491862C2779134260 @default.
- W4285491862 hasConceptScore W4285491862C71924100 @default.
- W4285491862 hasIssue "5" @default.
- W4285491862 hasLocation W42854918621 @default.
- W4285491862 hasLocation W42854918622 @default.
- W4285491862 hasLocation W42854918623 @default.
- W4285491862 hasOpenAccess W4285491862 @default.
- W4285491862 hasPrimaryLocation W42854918621 @default.
- W4285491862 hasRelatedWork W2313076522 @default.
- W4285491862 hasRelatedWork W2765980456 @default.
- W4285491862 hasRelatedWork W2976382042 @default.
- W4285491862 hasRelatedWork W2981703979 @default.
- W4285491862 hasRelatedWork W3084216382 @default.
- W4285491862 hasRelatedWork W3209686377 @default.
- W4285491862 hasRelatedWork W3210359220 @default.
- W4285491862 hasRelatedWork W3217009132 @default.
- W4285491862 hasRelatedWork W4367672288 @default.
- W4285491862 hasRelatedWork W2464797648 @default.
- W4285491862 hasVolume "140" @default.
- W4285491862 isParatext "false" @default.
- W4285491862 isRetracted "false" @default.
- W4285491862 workType "article" @default.